Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege

Experimental Eye Research
Peter W ChenB R Ksander

Abstract

Immune privilege in the anterior chamber of the eye is very effective at preventing elimination of ocular tumors that express weak tumor antigens. We previously demonstrated that DBA/2 mice immunized in the flank with a P815 tumor cell vaccine that expressed CD80/IL-12 was unable to terminate immune privilege and prevent tumor growth in the anterior chamber. In the present study, we determined whether expression of costimulatory signals on tumor cells injected via an ocular route would terminate immune privilege. We observed that CD80-positive tumors were always rejected from the anterior chamber. However, the pattern of tumor rejection was dramatically different depending upon whether the mice were either naïve, or immunized in flank against the tumor cells. Naïve mice that received an anterior chamber injection of CD80-positive tumors did not develop immune privilege and displayed strong delayed hypersensitivity (DH) against the tumor cells. Moreover, the ocular tumors were rejected by ischemic necrosis that induced atrophy of the eye and phthisis. When immunized mice received an identical injection of tumor cells in the anterior chamber, they also did not develop immune privilege and displayed strong DH. However, tumor rejec...Continue Reading

References

May 1, 1988·Current Eye Research·J Y Niederkorn, T L Knisely
May 1, 1981·The Journal of Experimental Medicine·J W Streilein, J Y Niederkorn
Jan 1, 1981·Immunogenetics·J Y NiederkornJ W Streilein
Oct 31, 1996·Annals of the New York Academy of Sciences·P W ChenB R Ksander
Dec 6, 2001·Nature Reviews. Molecular Cell Biology·D R Green, T A Ferguson
Mar 26, 2002·Nature Reviews. Immunology·Arlene H Sharpe, Gordon J Freeman
Apr 4, 2002·Proceedings of the National Academy of Sciences of the United States of America·Geertje J D van MierloRene E M Toes
Jul 10, 2002·Trends in Immunology·Hinrich AbkenBarbara Seliger
Dec 12, 2003·Nature Reviews. Immunology·J Wayne Streilein
Mar 18, 2005·Annual Review of Immunology·Rebecca J GreenwaldArlene H Sharpe
Jul 16, 2005·Ocular Immunology and Inflammation·Jun-Song Mo, J Wayne Streilein
Jun 27, 2006·Investigative Ophthalmology & Visual Science·Zita F H M BoonmanMartine J Jager
Jan 1, 1995·Ocular Immunology and Inflammation·J W Streilein
Jan 1, 1996·Ocular Immunology and Inflammation·J W StreileinY Sano

❮ Previous
Next ❯

Citations

Dec 29, 2007·Current Opinion in Ophthalmology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.